BIAF (bioAffinity Technologies) Days Sales Outstanding : 56.75 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Days Sales Outstanding?

bioAffinity Technologies's average Accounts Receivable for the three months ended in Sep. 2024 was $1.46 Mil. bioAffinity Technologies's Revenue for the three months ended in Sep. 2024 was $2.35 Mil. Hence, bioAffinity Technologies's Days Sales Outstanding for the three months ended in Sep. 2024 was 56.75.

The historical rank and industry rank for bioAffinity Technologies's Days Sales Outstanding or its related term are showing as below:

BIAF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.27 Med: 129.37 Max: 146
Current: 46.27

During the past 4 years, bioAffinity Technologies's highest Days Sales Outstanding was 146.00. The lowest was 46.27. And the median was 129.37.

BIAF's Days Sales Outstanding is ranked better than
75.23% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 65.49 vs BIAF: 46.27

bioAffinity Technologies's Days Sales Outstanding declined from Sep. 2023 (183.42) to Sep. 2024 (56.75).

bioAffinity Technologies Days Sales Outstanding Historical Data

The historical data trend for bioAffinity Technologies's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Days Sales Outstanding Chart

bioAffinity Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

146.00

112.73

bioAffinity Technologies Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial											183.42	38.97	36.14	51.75	56.75

Competitive Comparison of bioAffinity Technologies's Days Sales Outstanding

For the Diagnostics & Research subindustry, bioAffinity Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Days Sales Outstanding falls into.

bioAffinity Technologies Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

bioAffinity Technologies's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0.782)	/	1 )	/	2.532	*	365
=	0.782					/	2.532	*	365
=	112.73

bioAffinity Technologies's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (1.596	+	1.327)	/	2 )	/	2.35	*	365 / 4
=	1.4615					/	2.35	*	365 / 4
=	56.75

bioAffinity Technologies (NAS:BIAF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

bioAffinity Technologies Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

bioAffinity Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Executives

Roby Joyce	director	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles	officer: Chief Operating Officer	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty	officer: Chief Financial Officer	2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards	officer: Chief Financial Officer	30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight	director	6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti	director, officer: Executive Chairman	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Gary D Rubin	director, 10 percent owner	2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond	director	498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes	director, officer: President, CEO	19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust	10 percent owner	21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji	director	C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel	officer: EVP, Chief Sci. & Med. Officer	8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes	officer: Secretary, EVP, Gen. Counsel	1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter	10 percent owner	28 PARRISH POND LANE, SOUTHAMPTON NY 11968